Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

Stocks Rally on AI Spending Optimism

View original at nasdaq.com
Stocks Rally on AI Spending Optimism The S&P 500 Index ($SPX) (SPY) today is up +0.28%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.81%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump is comfortable with recent weakness in the dollar

    80% confidence

  • S&P earnings growth is expected to climb by 8.4% in Q4

    80% confidence

  • Trump wants Iran to come to the table and negotiate a fair and equitable deal with no nuclear weapons

    80% confidence

  • The ECB would need to consider another interest rate cut if further increases in the euro's value were large enough to lower inflation projections

    80% confidence

  • Amphenol's sales forecast underwhelms despite robust Q4 beat, suggesting potential demand pull-forward

    80% confidence

  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by 4.6%

    80% confidence

  • Senate Democrats threatened to block a government funding deal over Department of Homeland Security/ICE funding after the ICE shooting in Minnesota

    80% confidence

  • Time is running out for Iran to make a deal with the US, with a fleet of US warships in the region ready to complete their mission with speed and violence

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com